ACUTE KIDNEY INJURY: Clinical trials in AKI: is the end in sight?

    loading  Checking for direct PDF access through Ovid

Abstract

Clinical trials in patients with acute kidney injury (AKI) have been stymied by a lack of consensus on suitable renal-specific end points. In a recent analysis, Grams et al. suggest that a sustained 30–40% reduction in estimated glomerular filtration rate after hospital discharge might be a suitable intermediate end point for AKI clinical trials.

Refers to Grams, M. E. et al. Candidate surrogate end points for ESRD after AKI. J. Am. Soc. Nephrol.http://dx.doi.org/10.1681/ASN.2015070829

Related Topics

    loading  Loading Related Articles